Collaboration with CMS contributed to proposed Medicare coverage.
The U.S. Food and Drug Administration today approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or precursors to cancer.
Exact Sciences Corp., Center for Devices and Radiological Health (CDRH), Centers for Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA)
News Well, Press Release, Regulatory/Clearance, Genomics/Molecular Diagnostics, Medicare, Oncology, Pre-Market Approval (PMA), Reimbursement
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1oL9ixk
Cap comentari:
Publica un comentari a l'entrada